WuXi Biologics (药明生物; WuXi Biologics (Cayman) Inc.) is a global contract research, development, and manufacturing organization (CRDMO) focused on biopharmaceuticals. The company provides end-to-end services covering cell line development, process and analytical development, technology transfer, and GMP manufacturing of drug substance and drug product, including sterile fill–finish for vials and pre-filled syringes. Its platforms support monoclonal antibodies and other recombinant protein therapeutics.
Headquartered in Wuxi, China and listed in Hong Kong, WuXi Biologics operates a network of GMP facilities across Asia, Europe, and North America, utilizing single-use and perfusion bioreactor technologies. The company applies Quality by Design principles, process analytical technologies, and integrated digital systems to enable scale-up and lifecycle management. WuXi Biologics serves global biopharmaceutical customers under multi-site quality systems with regulatory approvals from major health authorities such as the FDA, EMA, and China’s NMPA.
Official website: wuxibiologics.com
To provide comprehensive coverage, we aggregate data and news under the name WuXi, encompassing the following company names, divisions, and related entities:
WuXi Biologics (Cayman) Inc. and 药明生物.
This list encompasses current and former names, alternate names, and key divisions associated with WuXi, ensuring you can easily find all relevant information under a single, unified profile.
